Literature DB >> 24127995

Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma.

A Broniscer1, R G Tatevossian, N D Sabin, P Klimo, J Dalton, R Lee, A Gajjar, D W Ellison.   

Abstract

AIMS: A few case series in adults have described the characteristics of epithelioid glioblastoma (e-GB), one of the rarest variants of this cancer. We evaluated clinical, radiological, histological and molecular characteristics in the largest series to date of paediatric e-GB.
METHODS: Review of clinical characteristics and therapy, imaging studies and histology was performed in patients younger than 22 years with e-GB seen at our institution over 15 years. Sequencing of hotspot mutations and fluorescence in situ hybridization of relevant genes were undertaken.
RESULTS: Median age at diagnosis of six patients was 7.6 years. Tumours originated in the cerebral cortex (n = 2) or diencephalon (n = 4). Three patients presented with acute, massive haemorrhage and three had leptomeningeal dissemination at diagnosis. Paediatric e-GB had the typical histological characteristics seen in adult tumours. Universal immunoreactivity for INI1 and lack of diverse protein expression were seen in all cases. One tumour had a chromosome 22q loss. Three tumours (50%) harboured a BRAF: p.V600E. One thalamic tumour had an H3F3A p.K27M. All patients received radiation therapy with (n = 3) or without chemotherapy (n = 3). All patients experienced tumour progression with a median survival of 169 days. One patient with nonmetastatic disease had early leptomeningeal progression. Two patients had symptomatic tumour spread outside the central nervous system (CNS) through a ventriculoperitoneal shunt. One additional patient had widespread metastases outside the CNS identified at autopsy.
CONCLUSIONS: Paediatric e-GBs are rare cancers with an aggressive behaviour that share histological and genetic characteristics with their adult counterparts. BRAF inhibition is a potential treatment for these tumours.
© 2013 British Neuropathological Society.

Entities:  

Keywords:  BRAF; epithelioid; glioblastoma; paediatric; rhabdoid

Mesh:

Year:  2014        PMID: 24127995      PMCID: PMC4042629          DOI: 10.1111/nan.12093

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  38 in total

1.  Molecular genetic alterations in glioblastomas with oligodendroglial component.

Authors:  J A Kraus; K Lamszus; N Glesmann; M Beck; M Wolter; M Sabel; D Krex; T Klockgether; G Reifenberger; U Schlegel
Journal:  Acta Neuropathol       Date:  2001-04       Impact factor: 17.088

2.  Rhabdoid glioblastoma.

Authors:  J Wyatt-Ashmead; B K Kleinschmidt-DeMasters; D A Hill; G W Mierau; L McGavran; S J Thompson; N K Foreman
Journal:  Clin Neuropathol       Date:  2001 Nov-Dec       Impact factor: 1.368

3.  Primary malignant rhabdoid tumors of the central nervous system: considerations about two cases of adulthood presentation.

Authors:  José Pimentel; Rita Silva; Teresa Pimentel
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

4.  Infiltrative astrocytomas with granular cell features (granular cell astrocytomas): a study of histopathologic features, grading, and outcome.

Authors:  Daniel J Brat; Bernd W Scheithauer; Rafael Medina-Flores; Marc K Rosenblum; Peter C Burger
Journal:  Am J Surg Pathol       Date:  2002-06       Impact factor: 6.394

5.  Gliosarcoma with epithelial differentiation: immunohistochemical and molecular characterization. A case report and review of the literature.

Authors:  John A Ozolek; Sydney D Finkelstein; Marta E Couce
Journal:  Mod Pathol       Date:  2004-06       Impact factor: 7.842

6.  Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance.

Authors:  S Wakai; K Yamakawa; S Manaka; K Takakura
Journal:  Neurosurgery       Date:  1982-04       Impact factor: 4.654

7.  Rhabdoid glioblastoma: a case report.

Authors:  Rahul Lath; Dag Unosson; Peter Blumbergs; Jurgen Stahl; Brian P Brophy
Journal:  J Clin Neurosci       Date:  2003-05       Impact factor: 1.961

8.  The clinical significance of "adenoid" formations of neoplastic astrocytes, imitating metastatic carcinoma, in gliosarcomas. A review of five cases.

Authors:  J J Kepes; K H Fulling; J H Garcia
Journal:  Clin Neuropathol       Date:  1982       Impact factor: 1.368

9.  Clinicopathological characteristics and treatment of rhabdoid glioblastoma.

Authors:  Ranjith Babu; Jeffrey Hatef; Roger E McLendon; Thomas J Cummings; John H Sampson; Allan H Friedman; Cory Adamson
Journal:  J Neurosurg       Date:  2013-05-03       Impact factor: 5.115

10.  Granular cell glioblastoma: a malignant granular cell neoplasm of astrocytic origin.

Authors:  M Kornfeld
Journal:  J Neuropathol Exp Neurol       Date:  1986-07       Impact factor: 3.685

View more
  29 in total

1.  Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.

Authors:  David A Solomon; Matthew D Wood; Tarik Tihan; Andrew W Bollen; Nalin Gupta; Joanna J J Phillips; Arie Perry
Journal:  Brain Pathol       Date:  2015-12-14       Impact factor: 6.508

2.  The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know.

Authors:  Sahil Chhabda; Olivia Carney; Felice D'Arco; Thomas S Jacques; Kshitij Mankad
Journal:  Quant Imaging Med Surg       Date:  2016-10

3.  Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.

Authors:  Alberto Broniscer; Sujuan Jia; Belinda Mandrell; Dima Hamideh; Jie Huang; Arzu Onar-Thomas; Amar Gajjar; Susana C Raimondi; Ruth G Tatevossian; Clinton F Stewart
Journal:  Pediatr Blood Cancer       Date:  2018-03-07       Impact factor: 3.167

4.  Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Authors:  Drew Pratt; Stefania Pittaluga; Maryknoll Palisoc; Patricia Fetsch; Liqiang Xi; Mark Raffeld; Mark R Gilbert; Martha Quezado
Journal:  J Neuropathol Exp Neurol       Date:  2017-08-01       Impact factor: 3.685

5.  Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.

Authors:  Michael Zhang; Richard Li; Erqi L Pollom; Arya Amini; Savita Dandapani; Gordon Li
Journal:  J Clin Neurosci       Date:  2020-11-06       Impact factor: 1.961

6.  Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines.

Authors:  Mirella Baroni; Suely Kazue Nagahashi Marie; Paola Fernanda Fedatto; Augusto Faria Andrade; Veridiana Kill Suazo; Gustavo Alencastro Veiga Cruzeiro; Rosane de Paula Queiroz; Luiz Gonzaga Tone; Carlos Alberto Scrideli
Journal:  J Neurooncol       Date:  2018-04-18       Impact factor: 4.130

Review 7.  Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic Challenges.

Authors:  Cristina Birzu; Suzanne Tran; Franck Bielle; Mehdi Touat; Karima Mokhtari; Nadia Younan; Dimitri Psimaras; Khe Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Oncologist       Date:  2020-08-31

8.  Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.

Authors:  Alberto Broniscer; Omar Chamdine; Scott Hwang; Tong Lin; Stanley Pounds; Arzu Onar-Thomas; Sheila Shurtleff; Sariah Allen; Amar Gajjar; Paul Northcott; Brent A Orr
Journal:  Acta Neuropathol       Date:  2016-01-07       Impact factor: 17.088

Review 9.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

10.  Rapid regression of glioblastoma following carmustine wafer implantation: A case report.

Authors:  Junya Fukai; Hiroki Nishibayashi; Yuji Uematsu; Yonehiro Kanemura; Koji Fujita; Naoyuki Nakao
Journal:  Mol Clin Oncol       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.